Intelligence Feed event · Equity · 2026-09-13

    Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1

    Question

    Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1

    Direct answer

    Eli Lilly is actively diversifying its revenue base outside of its core metabolic and diabetes franchise. The company's immunology division recorded $2.6 billion in revenue during the first half of 2026, marking a 9% annual rise and accounting for 6.1% of top-line sales. Growth was led by established treatments such as Taltz along with newer market entries Omvoh and Ebglyss. The expansion has been supported by multiple targeted acquisitions, including DICE Therapeutics, Morphic Holding, and Merida.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/eli-lilly-expands-non-incretin-growth-as-immunology-revenue-hits-2-6b-in-h1-a6248e

    EQUITY
    Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1
    Eli Lilly is actively diversifying its revenue base outside of its core metabolic and diabetes franchise. The company's immunology division recorded $2.6 billion in revenue during the first half of 2026, marking a 9% annual rise and accounting for 6.1% of top-line sales. Growth was led by established treatments such as Taltz along with newer market entries Omvoh and Ebglyss. The expansion has been supported by multiple targeted acquisitions, including DICE Therapeutics, Morphic Holding, and Merida.
    LLYABBV
    Impact
    67
    SEP 13
    SIG
    85%
    LLYABBV
    Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1
    Eli Lilly is actively diversifying its revenue base outside of its core metabolic and diabetes franchise. The company's immunology division recorded $2.6 billion in revenue during the first half of 2026, marking a 9% annual rise and accounting for 6.1% of top-line sales. Growth was led by established treatments such as Taltz along with newer market entries Omvoh and Ebglyss. The expansion has been supported by multiple targeted acquisitions, including DICE Therapeutics, Morphic Holding, and Merida.
    → Targeted integration of DICE, Morphic, and Merida expands non-GLP-1 pharmaceutical revenue streams, de-risking long-term patent concentration in incretin therapies.
    Impact
    Eli Lilly is actively diversifying its revenue base outside of its core metabolic and diabetes franchise. The company's immunology division recorded $2.6 billion in revenue during the first half of 2026, marking a 9% annual rise and accounting for 6.1% of top-line sales. Growth was led by established treatments such as Taltz along with newer market entries Omvoh and Ebglyss. The expansion has been supported by multiple targeted acquisitions, including DICE Therapeutics, Morphic Holding, and Merida.
    Affected
    LLYABBV
    Transmission
    Targeted integration of DICE, Morphic, and Merida expands non-GLP-1 pharmaceutical revenue streams, de-risking long-term patent concentration in incretin therapies.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYtherapeutic revenue diversification beyond GLP-1 drug classesUp1-3mLilly generated $2.6B in H1 immunology revenue with expanded pipeline assets.
    ABBVcompetitive pricing pressure in commercial immunology indicationsMixed1-3mOmvoh and Ebglyss compete in core inflammatory and atopic indications.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month